A Clinical Study of Tranilast in the Treatment of Sarcoidosis

Condition:   Sarcoidosis Intervention:   Drug: Tranilast Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Authors: Takuma K, Eri H, Satoshi I, Takashi O PMID: 30333400 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
Cardiac resynchronization therapy (CRT) has been shown to be beneficial in patients with medically refractory heart failure. While it has been found to be effective in a wide range of etiologies for non-ischemic cardiomyopathy, its role in improving remodeling and survival of patients with cardiac sarcoidosis (CS) remains undefined. We performed a retrospective review of all patients at our institution with CS who underwent implantation of a CRT device between 2007 and 2017. The outcomes of this population were compared to the outcomes of a cohort of patients with non-ischemic cardiomyopathy with an etiology other than sarcoidosis.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 18 October 2018Source: Respiratory Medicine Case ReportsAuthor(s): Mari Tone, Nobuyasu Awano, Minoru Inomata, Naoyuki Kuse, Tatsunori Jo, Hanako Yoshimura, Yoshiaki Furuhata, Tamiko Takemura, Toshio Kumasaka, Takehiro IzumoAbstractCorrect staging of lung cancer is important for the selection of the best therapy, but discriminating between lymphadenopathy from lung cancer and from sarcoidosis by imaging examinations is difficult. Additionally, distinguishing lymphadenopathy of sarcoidosis from sarcoid reactions which are sometimes caused by lung cancer is difficult on imaging and pathologi...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
It was with great interest we read the article by Dr. Collins and colleagues published in the August 2018 edition of Respiratory Medicine, titled “Sarcoidosis and IPF in the same patient-a coincidence, an association or a phenotype?” The authors describe the characteristics of a disease entity they coined “combined sarcoidosis and idiopathic pulmonary fibrosis (CSIPF)” [1]. We appreciate the authors’ efforts to shed light on this cl inical entity, which to date has sparked debate in terms of proper classification of patients who share radiographic and histopathologic features of sarcoidosis an...
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Tags: Correspondence Source Type: research
Immunotherapy,Volume 10, Issue 14, Page 1189-1192, October 2018.
Source: Immunotherapy - Category: Allergy & Immunology Authors: Source Type: research
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Extrathoracic Sarcoidosis Interventions:   Drug: Infliximab;   Drug: Placebo Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Extrathoracic Sarcoidosis Interventions:   Drug: Infliximab;   Drug: Placebo Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Cardiac Sarcoidosis Interventions:   Other: 18F-FDG;   Drug: Prednisolone Sponsor:   University of Edinburgh Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Hospitals | Sarcoidosis | Study